SK15442000A3 - Kompozícia obsahujúca l-karnitín alebo alkanoyl-l-karnitín a nikotínamid adenín dinukleotid a/alebo nikotínamid adenín dinukleotid fosfát - Google Patents

Kompozícia obsahujúca l-karnitín alebo alkanoyl-l-karnitín a nikotínamid adenín dinukleotid a/alebo nikotínamid adenín dinukleotid fosfát Download PDF

Info

Publication number: SK15442000A3
Authority: SK; Slovakia
Prior art keywords: carnitine; composition; nadh; alkanoyl; adenine dinucleotide
Prior art date: 1998-04-17

Application number

SK1544-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Claudio Cavazza

Original Assignee

Sigma-Tau Healthscience S. P. A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-17

Filing date

1999-04-14

Publication date

2001-06-11

1999-04-14 Application filed by Sigma-Tau Healthscience S. P. A. filed Critical Sigma-Tau Healthscience S. P. A.

2001-06-11 Publication of SK15442000A3 publication Critical patent/SK15442000A3/sk

Links

PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title claims abstract description 56
239000000203 mixture Substances 0.000 title claims abstract description 24
-1 alkanoyl l-carnitine Chemical compound 0.000 title claims abstract description 14
229960001518 levocarnitine Drugs 0.000 title 2
ACFIXJIJDZMPPO-NCHANQSKSA-N nadph Chemical compound C1=CCC(C(=O)N)=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2[C@@H]([C@H](OP(O)(O)=O)[C@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NCHANQSKSA-N 0.000 title 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims abstract description 78
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims abstract description 69
239000003814 drug Substances 0.000 claims abstract description 18
150000003839 salts Chemical class 0.000 claims abstract description 14
208000018737 Parkinson disease Diseases 0.000 claims abstract description 11
235000015872 dietary supplement Nutrition 0.000 claims abstract description 6
238000011282 treatment Methods 0.000 claims description 17
229940079593 drug Drugs 0.000 claims description 13
ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 claims description 12
208000027089 Parkinsonian disease Diseases 0.000 claims description 9
206010034010 Parkinsonism Diseases 0.000 claims description 9
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 8
125000002252 acyl group Chemical group 0.000 claims description 8
239000002243 precursor Substances 0.000 claims description 8
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims description 7
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 6
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
239000005515 coenzyme Substances 0.000 claims description 6
UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 claims description 5
229950006238 nadide Drugs 0.000 claims description 5
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
239000002552 dosage form Substances 0.000 claims description 3
229960003966 nicotinamide Drugs 0.000 claims description 3
235000005152 nicotinamide Nutrition 0.000 claims description 3
239000011570 nicotinamide Substances 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
QWYFHHGCZUCMBN-SECBINFHSA-N O-butanoyl-L-carnitine Chemical compound CCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C QWYFHHGCZUCMBN-SECBINFHSA-N 0.000 claims description 2
VSNFQQXVMPSASB-SNVBAGLBSA-N O-valeroyl-L-carnitine Chemical compound CCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VSNFQQXVMPSASB-SNVBAGLBSA-N 0.000 claims description 2
229910019142 PO4 Inorganic materials 0.000 claims description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 2
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
239000003963 antioxidant agent Substances 0.000 claims description 2
229940009098 aspartate Drugs 0.000 claims description 2
235000003704 aspartic acid Nutrition 0.000 claims description 2
229960005261 aspartic acid Drugs 0.000 claims description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
229940001468 citrate Drugs 0.000 claims description 2
229960004106 citric acid Drugs 0.000 claims description 2
239000001530 fumaric acid Substances 0.000 claims description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 claims description 2
239000011976 maleic acid Substances 0.000 claims description 2
239000011707 mineral Substances 0.000 claims description 2
PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 2
235000006408 oxalic acid Nutrition 0.000 claims description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
239000010452 phosphate Substances 0.000 claims description 2
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 2
229940095064 tartrate Drugs 0.000 claims description 2
229940066528 trichloroacetate Drugs 0.000 claims description 2
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
229940088594 vitamin Drugs 0.000 claims description 2
229930003231 vitamin Natural products 0.000 claims description 2
235000013343 vitamin Nutrition 0.000 claims description 2
239000011782 vitamin Substances 0.000 claims description 2
XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 claims 2
DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims 2
229930024421 Adenine Natural products 0.000 claims 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
229960000643 adenine Drugs 0.000 claims 1
230000001939 inductive effect Effects 0.000 claims 1
206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract description 6
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract description 6
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 abstract 1
229960004203 carnitine Drugs 0.000 description 21
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 16
PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 15
238000012360 testing method Methods 0.000 description 15
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 13
230000000694 effects Effects 0.000 description 13
210000003205 muscle Anatomy 0.000 description 11
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 10
230000009467 reduction Effects 0.000 description 10
206010021143 Hypoxia Diseases 0.000 description 9
241001465754 Metazoa Species 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
229960003638 dopamine Drugs 0.000 description 8
230000007954 hypoxia Effects 0.000 description 8
241000699670 Mus sp. Species 0.000 description 7
IDAICLIJTRXNER-UHFFFAOYSA-N 5,6,7,8-tetrahydropteridine Chemical compound C1=NC=C2NCCNC2=N1 IDAICLIJTRXNER-UHFFFAOYSA-N 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
238000000034 method Methods 0.000 description 6
ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 5
238000003556 assay Methods 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
235000017471 coenzyme Q10 Nutrition 0.000 description 5
230000007812 deficiency Effects 0.000 description 5
201000010099 disease Diseases 0.000 description 5
210000003540 papillary muscle Anatomy 0.000 description 5
239000000758 substrate Substances 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
229940110767 coenzyme Q10 Drugs 0.000 description 4
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000007689 inspection Methods 0.000 description 4
229960004502 levodopa Drugs 0.000 description 4
230000007774 longterm Effects 0.000 description 4
230000002438 mitochondrial effect Effects 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
230000037081 physical activity Effects 0.000 description 4
230000003449 preventive effect Effects 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
102100022317 Dihydropteridine reductase Human genes 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
241000700159 Rattus Species 0.000 description 3
101710088929 Voltage-dependent L-type calcium channel subunit alpha-1S Proteins 0.000 description 3
239000002253 acid Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
206010016256 fatigue Diseases 0.000 description 3
230000006870 function Effects 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
230000004899 motility Effects 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
WGVIDFOIIXIJGV-UHFFFAOYSA-N 1-butan-2-yloxy-4-phenylpiperidine Chemical compound CC(CC)ON1CCC(CC1)C1=CC=CC=C1 WGVIDFOIIXIJGV-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108010066477 Carnitine O-acetyltransferase Proteins 0.000 description 2
102100036357 Carnitine O-acetyltransferase Human genes 0.000 description 2
108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 2
102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 2
206010058892 Carnitine deficiency Diseases 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
102000018832 Cytochromes Human genes 0.000 description 2
108010052832 Cytochromes Proteins 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
208000031226 Hyperlipidaemia Diseases 0.000 description 2
102000003960 Ligases Human genes 0.000 description 2
108090000364 Ligases Proteins 0.000 description 2
208000007873 MPTP Poisoning Diseases 0.000 description 2
CNIUEVQJABPUIJ-QMMMGPOBSA-N N-hydroxytyrosine Chemical compound ON[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNIUEVQJABPUIJ-QMMMGPOBSA-N 0.000 description 2
BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
206010029260 Neuroblastoma Diseases 0.000 description 2
102000004316 Oxidoreductases Human genes 0.000 description 2
108090000854 Oxidoreductases Proteins 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 2
102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
125000001589 carboacyl group Chemical group 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
108010076625 carnitine octanoyltransferase Proteins 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
230000006872 improvement Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000002045 lasting effect Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000035806 respiratory chain Effects 0.000 description 2
210000002027 skeletal muscle Anatomy 0.000 description 2
230000003319 supportive effect Effects 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
208000016505 systemic primary carnitine deficiency disease Diseases 0.000 description 2
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
AEDORKVKMIVLBW-BLDDREHASA-N 3-oxo-3-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]oxan-2-yl]methoxy]propanoic acid Chemical compound OCC1=C(O)C(C)=NC=C1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O1 AEDORKVKMIVLBW-BLDDREHASA-N 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
206010002660 Anoxia Diseases 0.000 description 1
241000976983 Anoxia Species 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
208000037157 Azotemia Diseases 0.000 description 1
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
206010010305 Confusional state Diseases 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 1
108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
208000017170 Lipid metabolism disease Diseases 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
206010049565 Muscle fatigue Diseases 0.000 description 1
208000021642 Muscular disease Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
201000009623 Myopathy Diseases 0.000 description 1
102000006746 NADH Dehydrogenase Human genes 0.000 description 1
108010086428 NADH Dehydrogenase Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
101710138657 Neurotoxin Proteins 0.000 description 1
206010031127 Orthostatic hypotension Diseases 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000007953 anoxia Effects 0.000 description 1
230000002930 anti-sclerotic effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
206010003549 asthenia Diseases 0.000 description 1
238000009534 blood test Methods 0.000 description 1
ZCHMSSOGPAFJTM-UHFFFAOYSA-N butanedioic acid 1-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CCC(O)=O.OC(C(CC(O)=O)C(O)=O)C(O)=O ZCHMSSOGPAFJTM-UHFFFAOYSA-N 0.000 description 1
FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229960004205 carbidopa Drugs 0.000 description 1
TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
210000005064 dopaminergic neuron Anatomy 0.000 description 1
230000000142 dyskinetic effect Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000001729 effect on metabolism Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000009088 enzymatic function Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
208000020346 hyperlipoproteinemia Diseases 0.000 description 1
206010020765 hypersomnia Diseases 0.000 description 1
230000003483 hypokinetic effect Effects 0.000 description 1
239000002117 illicit drug Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
231100001252 long-term toxicity Toxicity 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
210000001700 mitochondrial membrane Anatomy 0.000 description 1
230000037257 muscle growth Effects 0.000 description 1
208000013465 muscle pain Diseases 0.000 description 1
230000003387 muscular Effects 0.000 description 1
230000036473 myasthenia Effects 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
101150006061 neur gene Proteins 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
230000003557 neuropsychological effect Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
239000002581 neurotoxin Substances 0.000 description 1
231100000618 neurotoxin Toxicity 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
238000010606 normalization Methods 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
230000010627 oxidative phosphorylation Effects 0.000 description 1
150000002926 oxygen Chemical class 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
229950000688 phenothiazine Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
229960003147 reserpine Drugs 0.000 description 1
230000027756 respiratory electron transport chain Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
239000011669 selenium Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000011667 skeletal muscle adaptation Effects 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
210000003699 striated muscle Anatomy 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000009044 synergistic interaction Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
235000021476 total parenteral nutrition Nutrition 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
238000012549 training Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
201000002282 venous insufficiency Diseases 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Psychology (AREA)
Nutrition Science (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK1544-2000A 1998-04-17 1999-04-14 Kompozícia obsahujúca l-karnitín alebo alkanoyl-l-karnitín a nikotínamid adenín dinukleotid a/alebo nikotínamid adenín dinukleotid fosfát SK15442000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT98RM000238A IT1299161B1 (it)	1998-04-17	1998-04-17	Composizione comprendente l-carnitina o un'alcanoil l-carnitina e nadh e/o nadph
PCT/IT1999/000088 WO1999053921A1 (en)	1998-04-17	1999-04-14	Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph

Publications (1)

Publication Number	Publication Date
SK15442000A3 true SK15442000A3 (sk)	2001-06-11

Family

ID=11405812

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1544-2000A SK15442000A3 (sk)	1998-04-17	1999-04-14	Kompozícia obsahujúca l-karnitín alebo alkanoyl-l-karnitín a nikotínamid adenín dinukleotid a/alebo nikotínamid adenín dinukleotid fosfát

Country Status (17)

Country	Link
EP (1)	EP1071424A1 (et)
JP (1)	JP2002512191A (et)
KR (1)	KR20010042765A (et)
CN (1)	CN1299283A (et)
AU (1)	AU750645B2 (et)
BR (1)	BR9909712A (et)
CA (1)	CA2328331A1 (et)
EE (1)	EE200000601A (et)
HU (1)	HUP0101914A3 (et)
IL (1)	IL139014A0 (et)
IS (1)	IS5663A (et)
IT (1)	IT1299161B1 (et)
NO (1)	NO20005128L (et)
PL (1)	PL343482A1 (et)
SK (1)	SK15442000A3 (et)
TR (1)	TR200002894T2 (et)
WO (1)	WO1999053921A1 (et)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8252309B2 (en)	2000-04-04	2012-08-28	Sigma-Tau Industrie Farmaceutiche Riunite Spa	Dietary supplement energy-providing to skeletal muscles
DE10326822A1 (de) *	2003-06-11	2005-01-05	Herzpharma Vita-Check Diagnosegeräte GmbH	Mittel zur Nahrungsergänzung, dieses Mittel enthaltende pharmazeutische Präparate und Verwendungen des Mittels
AU2007353211B2 (en) *	2007-05-11	2013-08-29	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Gel useful for the delivery of cosmetic active ingredients
WO2011022786A1 (en) *	2009-08-31	2011-03-03	Pharmaqest Pty Ltd	Methods for diagnosis and treatment of chronic fatigue syndrome
CN104306390A (zh) *	2014-10-23	2015-01-28	苏州人本药业有限公司	还原型辅酶ⅱ的用途
CN104840479A (zh) *	2015-02-17	2015-08-19	苏州人本药业有限公司	Nadph在制备治疗心脏疾病药物中的应用
US10894059B2 (en) *	2017-12-22	2021-01-19	Bontac Bio-Engineering (Shenzhen) Co., Ltd	NADH compound composition, and preparation and use thereof
EP3755160B1 (de)	2018-04-20	2021-11-03	Pacotrade AG	Vorrichtung zum zerkleinern von in blockform bereitgestellten tiefgefrorenen lebensmitteln
CN109170907A (zh) *	2018-08-30	2019-01-11	泓博元生命科技（深圳）有限公司	一种含有nmn的组合物、应用及运动饮料的制备方法
CN109105702A (zh) *	2018-08-30	2019-01-01	泓博元生命科技（深圳）有限公司	一种含有nadh的组合物、应用及能量补充剂的制备方法
JP7199518B2 (ja) *	2018-10-10	2023-01-05	蘇娥梁	補虚損用ヘルスケア製品組成物、その製造方法及び使用
CN117958433A (zh) *	2024-03-22	2024-05-03	四川新渔新美健康科技有限公司	不含咖啡因的抗疲劳功能组合物、饮料

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1054698A (et) *	1964-12-04
US5292538A (en) *	1992-07-22	1994-03-08	Metagenics, Inc.	Improved sustained energy and anabolic composition and method of making
DE4335454A1 (de) *	1993-10-19	1995-04-20	Schleicher Peter	Geriatrikum
JPH09110708A (ja) *	1995-08-11	1997-04-28	Taisho Pharmaceut Co Ltd	滋養強壮用生薬配合製剤
JPH0959161A (ja) *	1995-08-23	1997-03-04	Taisho Pharmaceut Co Ltd	疲労改善用組成物
IT1277953B1 (it) *	1995-12-21	1997-11-12	Sigma Tau Ind Farmaceuti	Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
IT1283951B1 (it) *	1996-03-15	1998-05-07	Mendes Srl	Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di
US5712259A (en) *	1996-04-22	1998-01-27	Birkmayer Pharmaceuticals	NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US6077828A (en) *	1996-04-25	2000-06-20	Abbott Laboratories	Method for the prevention and treatment of cachexia and anorexia
JPH10175856A (ja) *	1996-10-14	1998-06-30	Taisho Pharmaceut Co Ltd	疲労改善剤

1998
- 1998-04-17 IT IT98RM000238A patent/IT1299161B1/it active IP Right Grant
1999
- 1999-04-14 WO PCT/IT1999/000088 patent/WO1999053921A1/en not_active Ceased
- 1999-04-14 TR TR2000/02894T patent/TR200002894T2/xx unknown
- 1999-04-14 CA CA002328331A patent/CA2328331A1/en not_active Abandoned
- 1999-04-14 EP EP99916039A patent/EP1071424A1/en not_active Withdrawn
- 1999-04-14 AU AU34428/99A patent/AU750645B2/en not_active Ceased
- 1999-04-14 JP JP2000544325A patent/JP2002512191A/ja active Pending
- 1999-04-14 SK SK1544-2000A patent/SK15442000A3/sk unknown
- 1999-04-14 PL PL99343482A patent/PL343482A1/xx not_active Application Discontinuation
- 1999-04-14 HU HU0101914A patent/HUP0101914A3/hu unknown
- 1999-04-14 KR KR1020007011499A patent/KR20010042765A/ko not_active Withdrawn
- 1999-04-14 IL IL13901499A patent/IL139014A0/xx unknown
- 1999-04-14 BR BR9909712-5A patent/BR9909712A/pt not_active IP Right Cessation
- 1999-04-14 CN CN99805644A patent/CN1299283A/zh active Pending
- 1999-04-14 EE EEP200000601A patent/EE200000601A/et unknown
2000
- 2000-10-12 NO NO20005128A patent/NO20005128L/no not_active Application Discontinuation
- 2000-10-13 IS IS5663A patent/IS5663A/is unknown

Also Published As

Publication number	Publication date
BR9909712A (pt)	2000-12-26
HUP0101914A2 (hu)	2002-03-28
ITRM980238A1 (it)	1999-10-17
IL139014A0 (en)	2001-11-25
IT1299161B1 (it)	2000-02-29
AU750645B2 (en)	2002-07-25
AU3442899A (en)	1999-11-08
CN1299283A (zh)	2001-06-13
PL343482A1 (en)	2001-08-27
NO20005128L (no)	2000-12-18
NO20005128D0 (no)	2000-10-12
HUP0101914A3 (en)	2002-12-28
IS5663A (is)	2000-10-13
EE200000601A (et)	2002-04-15
JP2002512191A (ja)	2002-04-23
TR200002894T2 (tr)	2001-01-22
CA2328331A1 (en)	1999-10-28
EP1071424A1 (en)	2001-01-31
WO1999053921A1 (en)	1999-10-28
KR20010042765A (ko)	2001-05-25
ITRM980238A0 (it)	1998-04-17

Publication	Publication Date	Title
EP0973415B1 (en)	2001-07-04	Nutritional supplement
EP1948155B1 (en)	2012-03-07	Pharmaceutical compositions comprising droxidopa
US8747906B2 (en)	2014-06-10	Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose
JPH01294688A (ja)	1989-11-28	パーキンソン症候群の治療用医薬、およびその製造方法
SK15442000A3 (sk)	2001-06-11	Kompozícia obsahujúca l-karnitín alebo alkanoyl-l-karnitín a nikotínamid adenín dinukleotid a/alebo nikotínamid adenín dinukleotid fosfát
US20250108020A1 (en)	2025-04-03	Compositions and compounds containng beta-hydroxybutyrate and one or more amino acids
HUP0202298A2 (en)	2002-10-28	Composition for the prevention of muscle fatigue and skeletal muscle adaptation to strenuous exercise
US8207109B2 (en)	2012-06-26	Food supplement with a slimming effect
Maddrey	1985	Branched chain amino acid therapy in liver disease.
CZ20014077A3 (cs)	2002-03-13	Doplňková výľiva dodávající energii kosternímu svalstvu a chránící kardiovaskulární systém
MXPA00009983A (en)	2001-11-21	Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph
CZ20003831A3 (cs)	2001-04-11	Přípravek obsahující L-karnitin nebo alkanoyl Lkarnitinu a NADH a/nebo NADPH
CA2400959C (en)	2011-01-04	Composition for the prevention and/or treatment of vascular diseases, comprising propionyl l-carnitine and coenzyme q10
HK1036589A (en)	2002-01-11	Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph
US20250332128A1 (en)	2025-10-30	Compositions and compounds containng ketone bodies and/or ketone body precursors and one or more amino acids
US20060025475A1 (en)	2006-02-02	Use of methyl pyruvate for the purpose of increasing muscle energy production.
EP0539336A1 (en)	1993-04-28	Use of L-carnitine or of acyl L-carnitine for the treatment of idiopathic oligoasthenospermias
GB2178661A (en)	1987-02-18	Pharmaceutical compositions containing ubiquinone coenzymes
RU2153880C1 (ru)	2000-08-10	Общеукрепляющее средство для профилактики и лечения заболеваний сердечно-сосудистой системы
CN118871096A (zh)	2024-10-29	包含l-色氨酸、l-5-羟基色氨酸和外周降解抑制剂的药物组合物和药物
CZ347999A3 (cs)	2000-02-16	Doplňková výživa pro snazší adaptaci kosterního svalstva vyčerpaného zatěžujícími výkony a paralyzování únavy asthenických jedinců
WO2000041686A1 (en)	2000-07-20	Treatment of hypertension with compounds that inhibit the destruction of enkephalins or endorphins
MXPA99008999A (en)	2000-02-02	Nutritional supplement for facilitating skeletal muscle adaptation to strenuous exercise and counteracting defatigation in asthenic individuals
RU2000129144A (ru)	2002-12-20	Композиция, включающая l-карнитин или алканоил l-карнитин и nadh и/или nadph
HK1026124B (en)	2002-04-19	Nutritional supplement